Aurinia Pharm Ord (AUPH) Stock Price, Quote & News

Company Profile

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was fou...

Industry: Biotechnology

Sector: Healthcare

Phone: 250 744 2487

Fax: 250 708 4345

Website: www.auriniapharma.com

Address:

#140, 14315 – 118 Avenue, Edmonton, Canada

Dallas9 Jul. 23 at 5:23 AM

$AUPH

0 · Reply

Hopenitsgood Jul. 23 at 2:48 AM

$AUPH Dropped 18% in a month. Just a Peter-puppet?

1 · Reply

Auphiliate Jul. 23 at 2:36 AM

$AUPH https://www.biospace.com/business/tang-seizes-control-of-aurinia-taking-ceo-post-in-total-transformation-of-c-suite

0 · Reply

Auphiliate Jul. 23 at 2:34 AM

$AUPH Anybody else see this?

1 · Reply

SuperGreenToday Jul. 22 at 11:01 PM

$AUPH Share Price: $15.34 Contract Selected: Jan 15, 2027 $15 Calls Buy Zone: $1.70 – $2.10 Target Zone: $2.89 – $3.53 Potential Upside: 61% ROI Time to Expiration: 176 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

diegomontana Jul. 22 at 9:21 PM

$AUPH

1 · Reply

tothebeach Jul. 22 at 9:17 PM

$AUPH watch the man tang take it all!!!! will never get bought out by big pharma thats a gaurantee

1 · Reply

Judge_Smails Jul. 22 at 8:41 PM

$AUPH this kid is clearly an AUPH long. https://x.com/badger69420/status/2079933149962764449?s=46&t=9lvwJKHtBRjYCChn69qH7A

1 · Reply

Yarrow Jul. 22 at 7:33 PM

$AUPH Why we not hiring a CEO?

0 · Reply

Bustingline Jul. 22 at 7:04 PM

$AUPH VERY INTERESTING - lack of communication = lack of interest. IMO

1 · Reply

Aurinia Pharmaceuticals announces initiation of PRESERVE study

Jul 6, 2026, 8:00 AM EDT - 16 days ago

Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis

2026-06-04T11:05:11.000Z - 6 weeks ago

Aurinia presents new analysis of AURORA 1 Phase 3 study of Lupkynis

Jun 4, 2026, 7:00 AM EDT - 6 weeks ago

LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death

2026-06-03T12:54:12.000Z - 7 weeks ago

Aurinia Pharmaceuticals up 4% in pre-market after insider transactions

2026-05-07T13:32:18.000Z - 2 months ago

Aurinia Pharmaceuticals reports Q1 EPS 25c, consensus 20c

May 7, 2026, 8:00 AM EDT - 2 months ago

Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress

May 7, 2026, 8:00 AM EDT - 2 months ago

Aurinia Pharmaceuticals Earnings release: Q1 2026

May 7, 2026, 8:00 AM EDT - 2 months ago

Aurinia Pharmaceuticals Quarterly report: Q1 2026

Apr 21, 2026, 8:00 AM EDT - 3 months ago

Aurinia Pharmaceuticals Proxy statement: Proxy filing

2026-03-30T19:56:09.000Z - 4 months ago

Kezar Life Sciences takeover valuation ‘makes sense,’ says Jefferies

KZR

2026-03-30T12:27:13.000Z - 4 months ago

Aurinia to acquire Kezar Life Sciences for $6.955 in cash per share plus CVR

KZR

Mar 30, 2026, 8:00 AM EDT - 4 months ago

Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right

KZR

2026-03-23T15:06:50.000Z - 4 months ago

MKT Capital ‘applauds’ Aurinia’s management transition

Mar 23, 2026, 11:00 AM EDT - 4 months ago

MKT Capital Applauds Aurinia Pharmaceuticals' Management Transition

2026-03-23T12:05:26.000Z - 4 months ago

Aurinia Pharmaceuticals announces Tang to succeed Greenleaf as CEO

Mar 23, 2026, 8:00 AM EDT - 4 months ago

Aurinia Announces Management Transition

Feb 26, 2026, 8:30 AM EST - 5 months ago

Aurinia Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:30 AM EST - 5 months ago

Aurinia Pharmaceuticals Earnings release: Q4 2025

Feb 26, 2026, 8:30 AM EST - 5 months ago

Aurinia Pharmaceuticals Annual report: Q4 2025

2026-02-26T11:12:48.000Z - 5 months ago

Aurinia Pharmaceuticals reports Q4 EPS $1.53, consensus 22c

2026-02-26T11:11:58.000Z - 5 months ago

Aurinia Pharmaceuticals sees 2026 revenue $315M-$-325M, consensus $326.8M

Feb 26, 2026, 6:00 AM EST - 5 months ago

Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress

Feb 19, 2026, 6:00 AM EST - 5 months ago

Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026

2025-12-03T11:54:13.000Z - 8 months ago

Aurinia Pharmaceuticals downgraded to Market Perform from Outperform at Leerink

2025-12-03T11:10:14.000Z - 8 months ago

Aurinia Pharmaceuticals downgraded to Market Perform from Outperform at Leerink

2025-11-07T10:15:39.000Z - 9 months ago

Aurinia Pharmaceuticals upgraded to Buy from Hold at Jefferies

2025-11-04T21:47:14.000Z - 9 months ago

Aurinia downgraded to Sector Perform from Outperform at RBC Capital

Nov 4, 2025, 8:30 AM EST - 9 months ago

Aurinia Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:30 AM EST - 9 months ago

Aurinia Pharmaceuticals Earnings release: Q3 2025

Nov 4, 2025, 8:30 AM EST - 9 months ago

Aurinia Pharmaceuticals Quarterly report: Q3 2025

2025-11-04T11:15:36.000Z - 9 months ago

Aurinia Pharmaceuticals reports Q3 EPS 23c, consensus 16c

2025-11-04T11:15:16.000Z - 9 months ago

Aurinia Pharmaceuticals raises FY25 revenue view to $275M-$280M from $260M-$270M

Nov 4, 2025, 6:00 AM EST - 9 months ago

Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress

Nov 3, 2025, 6:00 AM EST - 9 months ago

Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025

Oct 15, 2025, 6:00 AM EDT - 10 months ago

Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025

Sep 29, 2025, 8:27 PM EDT - 10 months ago

Aurinia Responds to Now Retracted LinkedIn Post

Jul 31, 2025, 8:30 AM EDT - 1 year ago

Aurinia Pharmaceuticals Earnings Call Transcript: Q2 2025

Jul 31, 2025, 8:30 AM EDT - 1 year ago

Aurinia Pharmaceuticals Quarterly report: Q2 2025

Jul 31, 2025, 8:30 AM EDT - 1 year ago

Aurinia Pharmaceuticals Earnings release: Q2 2025

Jul 31, 2025, 6:00 AM EDT - 1 year ago

Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025

Jul 25, 2025, 7:00 AM EDT - 1 year ago

Aurinia Pharmaceuticals Slides: Corporate Presentation

Jul 22, 2025, 6:00 AM EDT - 1 year ago

Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025

Jun 30, 2025, 8:30 AM EDT - 1 year ago

Aurinia Pharmaceuticals Transcript: Study Result

Jun 30, 2025, 8:30 AM EDT - 1 year ago

Aurinia Pharmaceuticals Press release: Study Result

Jun 30, 2025, 8:30 AM EDT - 1 year ago

Aurinia Pharmaceuticals Slides: Study Result

Jun 30, 2025, 6:00 AM EDT - 1 year ago

Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)

Jun 29, 2025, 5:00 PM EDT - 1 year ago

Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025

Jun 27, 2025, 7:00 AM EDT - 1 year ago

Aurinia Pharmaceuticals Slides: Corporate Presentation

Jun 10, 2025, 3:45 PM EDT - 1 year ago

Aurinia Pharmaceuticals Slides: Corporate Presentation

May 22, 2025, 6:00 AM EDT - 1 year ago

New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis

May 12, 2025, 8:30 AM EDT - 1 year ago

Aurinia Pharmaceuticals Earnings Call Transcript: Q1 2025

May 12, 2025, 8:30 AM EDT - 1 year ago

Aurinia Pharmaceuticals Earnings release: Q1 2025

May 12, 2025, 8:30 AM EDT - 1 year ago

Aurinia Pharmaceuticals Quarterly report: Q1 2025

May 12, 2025, 6:00 AM EDT - 1 year ago

Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025

May 5, 2025, 6:00 AM EDT - 1 year ago

Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Aurinia Pharmaceuticals Proxy statement: Proxy Filing

Apr 30, 2025, 6:00 AM EDT - 1 year ago

Glass Lewis Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Aurinia Pharmaceuticals Proxy statement: Proxy Filing

Apr 29, 2025, 6:00 AM EDT - 1 year ago

ISS Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting

Apr 23, 2025, 4:05 PM EDT - 1 year ago

Concerned Shareholders of Aurinia Pharmaceuticals Announce Their Intention to Withhold Support for CEO Peter Greenleaf at 2025 Annual Meeting

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Aurinia Pharmaceuticals Proxy statement: Proxy Filing

Feb 27, 2025, 8:30 AM EST - 1 year ago

Aurinia Pharmaceuticals Earnings Call Transcript: Q4 2024

Feb 27, 2025, 8:30 AM EST - 1 year ago

Aurinia Pharmaceuticals Earnings release: Q4 2024

Feb 27, 2025, 8:30 AM EST - 1 year ago

Aurinia Pharmaceuticals Annual report: Q4 2024

Feb 27, 2025, 6:00 AM EST - 1 year ago

Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress

Feb 20, 2025, 4:05 PM EST - 1 year ago

Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025

Nov 18, 2024, 5:53 PM EST - 1 year ago

Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis

Nov 15, 2024, 6:00 AM EST - 1 year ago

Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024

Nov 14, 2024, 6:00 AM EST - 1 year ago

Aurinia to Participate in Jefferies London Healthcare Conference

Nov 7, 2024, 8:30 AM EST - 1 year ago

Aurinia Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 7, 2024, 8:30 AM EST - 1 year ago

Aurinia Pharmaceuticals Quarterly report: Q3 2024

Nov 7, 2024, 8:30 AM EST - 1 year ago

Aurinia Pharmaceuticals Earnings release: Q3 2024

Nov 7, 2024, 6:10 AM EST - 1 year ago

Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth

Nov 7, 2024, 6:00 AM EST - 1 year ago

Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development

Oct 30, 2024, 4:05 PM EDT - 1 year ago

Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024

Oct 11, 2024, 6:00 AM EDT - 1 year ago

Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024

Sep 24, 2024, 8:10 AM EDT - 1 year ago

Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis

Sep 17, 2024, 3:05 PM EDT - 2 years ago

Aurinia Pharmaceuticals Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 13, 2024, 6:00 AM EDT - 2 years ago

Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 12, 2024, 4:05 PM EDT - 2 years ago

Aurinia Announces Board Restructuring

Sep 5, 2024, 6:00 AM EDT - 2 years ago

Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial

Aug 28, 2024, 6:00 AM EDT - 2 years ago

Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference

Aug 13, 2024, 8:00 AM EDT - 2 years ago

Aurinia Pharmaceuticals Shareholder Calls for CEO Peter Greenleaf, Dr. Brinda Balakrishnan, and Dr. Robert Foster to Resign from the Board

Aug 1, 2024, 8:30 AM EDT - 2 years ago

Aurinia Pharmaceuticals Earnings Call Transcript: Q2 2024

Aug 1, 2024, 8:30 AM EDT - 2 years ago

Aurinia Pharmaceuticals Quarterly report: Q2 2024

Aug 1, 2024, 8:30 AM EDT - 2 years ago

Aurinia Pharmaceuticals Earnings release: Q2 2024

Aug 1, 2024, 6:00 AM EDT - 2 years ago

Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results

Jul 19, 2024, 6:00 AM EDT - 2 years ago

Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024

Jul 11, 2024, 3:27 PM EDT - 2 years ago

ILJIN SNT Co., Ltd. Calls on Board of Aurinia Pharmaceuticals to Honor Shareholders' Voices Expressed at the AGM

Jul 2, 2024, 6:00 AM EDT - 2 years ago

Aurinia to Participate in Upcoming Investor Healthcare Conferences

Jun 14, 2024, 12:16 PM EDT - 2 years ago

Aurinia Announces 2024 Annual General Meeting Results

Jun 5, 2024, 8:25 AM EDT - 2 years ago

Aurinia Pharmaceuticals Transcript: Jefferies 2024 Global Healthcare Conference

Jun 5, 2024, 6:00 AM EDT - 2 years ago

Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024

Jun 4, 2024, 5:30 PM EDT - 2 years ago

Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce

Jun 4, 2024, 8:00 AM EDT - 2 years ago

Aurinia Pharmaceuticals Proxy statement: Proxy Filing

Jun 4, 2024, 8:00 AM EDT - 2 years ago

Aurinia Pharmaceuticals Proxy statement: Proxy Filing

Jun 3, 2024, 6:30 PM EDT - 2 years ago

Aurinia Provides Update on Proxy Statement

Jun 3, 2024, 8:00 AM EDT - 2 years ago

Aurinia Pharmaceuticals Shareholder Urges Fellow Shareholders to Withhold Support for CEO Peter Greenleaf

May 30, 2024, 6:00 AM EDT - 2 years ago

Aurinia Will Attend 2024 Jefferies Global Healthcare Conference

May 15, 2024, 10:00 AM EDT - 2 years ago

Aurinia Pharmaceuticals Transcript: 2024 RBC Capital Markets Global Healthcare Conference

May 14, 2024, 6:00 AM EDT - 2 years ago

Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation's Spring Clinical Meeting 2024

May 9, 2024, 6:00 AM EDT - 2 years ago

Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024

May 7, 2024, 9:00 AM EDT - 2 years ago

Aurinia Pharmaceuticals Shareholder Urges Board of Directors to Take Action to Enhance Shareholder Value

Dallas9 Jul. 23 at 5:23 AM

$AUPH

0 · Reply

Hopenitsgood Jul. 23 at 2:48 AM

$AUPH Dropped 18% in a month. Just a Peter-puppet?

1 · Reply

Auphiliate Jul. 23 at 2:36 AM

$AUPH https://www.biospace.com/business/tang-seizes-control-of-aurinia-taking-ceo-post-in-total-transformation-of-c-suite

0 · Reply

Auphiliate Jul. 23 at 2:34 AM

$AUPH Anybody else see this?

1 · Reply

SuperGreenToday Jul. 22 at 11:01 PM

0 · Reply

diegomontana Jul. 22 at 9:21 PM

$AUPH

1 · Reply

tothebeach Jul. 22 at 9:17 PM

$AUPH watch the man tang take it all!!!! will never get bought out by big pharma thats a gaurantee

1 · Reply

Judge_Smails Jul. 22 at 8:41 PM

$AUPH this kid is clearly an AUPH long. https://x.com/badger69420/status/2079933149962764449?s=46&t=9lvwJKHtBRjYCChn69qH7A

1 · Reply

Yarrow Jul. 22 at 7:33 PM

$AUPH Why we not hiring a CEO?

0 · Reply

Bustingline Jul. 22 at 7:04 PM

$AUPH VERY INTERESTING - lack of communication = lack of interest. IMO

1 · Reply

Dameistro Jul. 22 at 6:09 PM

$AUPH 30mil profit last qrt is my guess!

0 · Reply

3D_STOCK_TRADING Jul. 22 at 5:59 PM

$AUPH I would rather Tang take a salary and also give his investors some disclosure. I have a feeling the "no salary" was a way to give retailers something to believe in while hedge funds and traders make a fortune as retailers hold the bag... as per usual.

0 · Reply

Yarrow Jul. 22 at 5:50 PM

$AUPH Should've sold a lot more at $18.85. Hate this stock.

0 · Reply

therightpicks Jul. 22 at 5:47 PM

$AUPH more silence

0 · Reply

3D_STOCK_TRADING Jul. 22 at 5:46 PM

$AUPH Tang is a scam artist. Look back at his history. Would not be suprised if he lent out a portion of his shares for someone to short. Actually, i would bet on it. I am bullish but my eyes are wide open. The Trump Admin are about a scammy as Tang is.

3 · Reply

hashtagzee Jul. 22 at 5:37 PM

$AUPH haven’t stopped by in a minute. Looks like this went over $19 recently? I hope you all sold. Is @ThomasLD still trying to swindle folks into investing on the buyout theory while secretly unloading shares? 🤣

0 · Reply

Perkun Jul. 22 at 5:28 PM

$AUPH ☀️

0 · Reply

LowerlowsHigherHighs Jul. 22 at 5:11 PM

$AUPH Stock was at 18.90 not 6 weeks ago and we have 3 days of low volume trading and you guys are screaming bloody murder. Investing may not be for you. This whole make quick money thing everyone fell into is a disease.

2 · Reply

ATzmansto Jul. 22 at 4:52 PM

$AUPH

1 · Reply

SCCT2FL Jul. 22 at 4:49 PM

$AUPH what's the hold up on any AUR200 news? They treat news around here like it's connected to the nuclear codes

0 · Reply

jdoldnumber7 Jul. 22 at 4:48 PM

$AUPH Today's half over and only 250K shares traded. Piss poor!

1 · Reply

VSTN Jul. 22 at 4:31 PM

$AUPH I think this is right around KT’s cost average …correct me if I’m wrong

1 · Reply

Market Cap	2.01B
Revenue (ttm)	283.06M
Net Income (ttm)	287.20M
EPS (ttm)	N/A
PE Ratio	16.94
Forward PE	18.65
Profit Margin	101.46%
Debt to Equity Ratio	0.00

Volume	838,300
Avg Vol	1,555,270
Day's Range	N/A - N/A
Shares Out	128.60M
Stochastic %K	12%
Beta	1.41
Analysts	Strong Sell
Price Target	$17.00